Licofelone
Analgesic and anti-inflammatory compound
- Investigational
- [6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid
- 156897-06-2
- 133021
- 117391
N
- P5T6BYS22Y
- ChEMBL52854
- DTXSID40166154
InChI
- InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)N
- Key:UAWXGRJVZSAUSZ-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Licofelone is a dual COX/LOX inhibitor[1][2] that was studied in clinical trials as a treatment for osteoarthritis[3] and which was under development by Merckle GmbH with partners Alfa Wassermann and Lacer.
Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-lipoxygenase (5-LOX) may reduce the gastrointestinal toxicity associated with other nonsteroidal anti-inflammatory drugs (NSAID), which only inhibit cyclooxygenase (COX). Licofelone is the first drug to inhibit both.
Phase III trials for osteoarthritis were conducted in the early 2000s,[4][5] but results were mixed and the drug has never been submitted for regulatory approval.
References
- ^ Fischer L, Hornig M, Pergola C, Meindl N, Franke L, Tanrikulu Y, et al. (October 2007). "The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products". British Journal of Pharmacology. 152 (4): 471–80. doi:10.1038/sj.bjp.0707416. PMC 2050828. PMID 17704828.
- ^ Vidal C, Gómez-Hernández A, Sánchez-Galán E, González A, Ortega L, Gómez-Gerique JA, et al. (January 2007). "Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis". The Journal of Pharmacology and Experimental Therapeutics. 320 (1): 108–16. doi:10.1124/jpet.106.110361. PMID 17015640. S2CID 73105840.
- ^ Alvaro-Gracia JM (February 2004). "Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis". Rheumatology. 43 Suppl 1 (90001): i21-5. doi:10.1093/rheumatology/keh105. PMID 14752172.
- ^ "Licofelone – Novel Analgesic and Anti-Inflammatory Agent for Osteoarthritis". Retrieved January 12, 2018.
- ^ Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP (December 2010). "Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI". Annals of the Rheumatic Diseases. 69 (12): 2118–24. doi:10.1136/ard.2009.127993. PMID 20610445. S2CID 206864399.
- v
- t
- e
Prostanoid signaling modulators
(ligands)
| DP (D2)Tooltip Prostaglandin D2 receptor |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EP (E2)Tooltip Prostaglandin E2 receptor |
| ||||||||||
| FP (F2α)Tooltip Prostaglandin F receptor |
| ||||||||||
| IP (I2)Tooltip Prostacyclin receptor |
| ||||||||||
| TP (TXA2)Tooltip Thromboxane receptor |
| ||||||||||
| Unsorted |
|
(inhibitors)
- Precursors: Linoleic acid
- γ-Linolenic acid (gamolenic acid)
- Dihomo-γ-linolenic acid
- Diacylglycerol
- Arachidonic acid
- Prostaglandin G2
- Prostaglandin H2
- See also
- Receptor/signaling modulators
- Leukotriene signaling modulators
